Macrilen is owned by Novo.
Macrilen contains Macimorelin Acetate.
Macrilen has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Macrilen are:
Macrilen was authorised for market use on 20 December, 2017.
Macrilen is available in for solution;oral dosage forms.
Macrilen can be used as a method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin.
Drug patent challenges can be filed against Macrilen from December, 2021.
The generics of Macrilen are possible to be released after 12 October, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6861409||NOVO||Growth hormone secretagogues|| |
(6 months ago)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8192719||NOVO||Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds|| |
(4 years from now)
|Orphan Drug Exclusivity (ODE)||Dec 20, 2024|
|New Chemical Entity Exclusivity (NCE)||Dec 20, 2022|
NCE-1 date: December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic